Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxyurea + Dose-Intense Temozolomide in Recurrent Glioblastoma
NCT03463733Phase 1Unknown
- Start
- Mar 2018
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hydroxyurea in glioblastoma (GBM). Primary endpoint: Maximal Tolerated Dose at 12 months. Status: unknown.
02
Drugs
hydroxyurea
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03463733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03463733.